RESEARCH

Spontaneous control of HIV-1 viremia in a subject with protective HLA-B plus HLA-C alleles and HLA-C associated single nucleotide polymorphisms

Marco Moroni1, Silvia Ghezzi2, Paolo Baroli3, Silvia Heltai4, Davide De Battista4, Simone Pensieroso5, Mariangela Cavarelli5, Stefania Dispini5, Irene Vanni6, Claudia Pastori7, Pietro Zerbi6, Antonella Tosoni8, Elisa Vicenzi2, Manuela Nebuloni8, Kim Wong9, Hong Zhao9, Sarah McHugh9, Guido Poli10,11, Lucia Lopalco7, Gabriella Scarlatti5, Roberto Biassoni6, James I Mullins9†, Mauro S Malnati4† and Massimo Alfano10,12*

Abstract

Introduction: Understanding the mechanisms by which some individuals are able to naturally control HIV-1 infection is an important goal of AIDS research. We here describe the case of an HIV-1+ woman, CASE1, who has spontaneously controlled her viremia for the last 14 of her 20 years of infection.

Methods: CASE1 has been clinically monitored since 1993. Detailed immunological, virological and histological analyses were performed on samples obtained between 2009 and 2011.

Results: As for other Elite Controllers, CASE1 is characterized by low to undetectable levels of plasma HIV-1 RNA, peripheral blood mononuclear cell (PBMC) associated HIV-1 DNA and reduced in vitro susceptibility of target cells to HIV-1 infection. Furthermore, a slow rate of virus evolution was demonstrated in spite the lack of assumption of any antiretroviral agent. CASE1 failed to transmit HIV-1 to either her sexual male partner or to her child born by vaginal delivery. Normal values and ratios of T and B cells were observed, along with normal histology of the intestinal mucosa. Attempts to isolate HIV-1 from her PBMC and gut-derived cells were unsuccessful, despite expression of normal cell surface levels of CD4, CCRC5 and CXCR4. CASE1 did not produce detectable anti-HIV neutralizing antibodies in her serum or genital mucosal fluid although she displayed potent T cell responses against HIV-1 Gag and Nef. CASE1 also possessed multiple genetic polymorphisms, including HLA alleles (B*14, B*57, C*06 and C*08.02) and HLA-C single nucleotide polymorphisms (SNPs, rs9264942 C/C and rs67384697 del/del), that have been previously individually associated with spontaneous control of plasma viremia, maintenance of high CD4+ T cell counts and delayed disease progression.

(Continued on next page)
Conclusions: CASE1 has controlled her HIV-1 viremia below the limit of detection in the absence of antiretroviral therapy for more than 14 years and has not shown any sign of immunologic deterioration or disease progression. Co-expression of multiple protective HLA alleles, HLA-C SNPs and strong T cell responses against HIV-1 proteins are the most likely explanation of this very benign case of spontaneous control of HIV-1 disease progression.

Keywords: Human Immunodeficiency Virus (HIV), Viremia, Human Leukocyte Antigen (HLA), Single Nucleotide Polymorphisms (SNPs), Elite controller (ELC), Long term nonprogressor (LTNP)

Introduction
In the absence of combination antiretroviral therapy (cART) HIV-1 infection results in AIDS and death in most individuals. In contrast, a minority of individuals demonstrate an almost absolute capacity to resist infection (e.g., carriers of CCR5-Δ32 homozygosity) [1]. Others, when infected, experience significantly delayed disease progression, either in terms of maintenance of peripheral CD4+ T cell counts ≥500 cells/μl after 7–8 years of HIV-1 infection (long-term non progressors, LTNP) or by spontaneously controlling their HIV viremia [commonly referred to as “Elite Controllers (ELC)” when 90% of plasma HIV-1 RNA values are <50 copies/ml, or “HIV Controllers (HIC)”, when 90% of plasma viremia measurements are <500 copies/ml for ≥12 months]. Rare (<1% of all infected individuals) cases show both LTNP and EC features and have been defined as "elite LTNP" [2,3].

Among other correlates of delayed HIV-1 progression in the absence of cART the role of several alleles of Human Leukocyte Antigen (HLA) Class I genes, such as HLA-B*27 [4] and HLA-B*57 [5] has been well established. Additional associations between MHC-Class I and III SNPs and the LTNP phenotype have been observed [6].

Thus, CASE1 detailed immunologic, virological and genetic profile may provide clues to the design of therapeutic vaccines aiming at achieving a functional cure of HIV-1 disease progression in the absence of ART [7].

Viral genetic analysis
Isolation of plasma HIV RNA and PBMC-associated HIV DNA, reverse transcription, amplification, gag and env sequencing were performed according to the published methods reported in the Additional file 1 section.

MiR-148a/b binding site (single nucleotide polymorphisms, SNP: rs67384697) and -35Kb 5′UTR HLA-C (SNP: rs9264942) analysis
Genomic DNA was extracted from CASE1’s PBMC using the PureLink Genomic DNA kit (Invitrogen, Carlsbad, CA), and a pyrosequencing approach was used to determine SNPs. Detailed methods are reported in the Additional file 1 section.

Culture and co-culture of rectal biopsy with allogeneic T cell blasts
Histocultures of intestinal biopsies were performed as previously reported [9]; both cells and histoculture supernatants were collected 24 h later. Cells were dispersed by enzymatic digestion with collagenase IV (0.5 mg/ml in complete culture medium, 30 min at 37°C), passed through a 22G needle and filtered with a 70 μm cell strainer. The digestion was repeated and cells from the two rounds were pooled and debris removed by centrifugation. Two million biopsy-derived cells were cultivated either alone or with 2x106 [6] PHA-stimulated PBMC from two different donors that had been previously depleted or not of CD8+ T cells by magnetic immunobeads. Both cultures and co-cultures were maintained for 30 days in IL-2 enriched medium, collecting their supernatants every 3 days for measurement of virus using either Mg++-dependent reverse transcriptase (RT) activity [10] or HIV-1 p24 Gag antigen by ELISA.

HIV-1 isolation from and ex-vivo infection of CASE1 PBMC
Three independent attempts were made to isolate HIV-1 from peripheral CD4+ T cells according to published protocols [11]. Supernatants were collected every 3–4 days for up to 4 weeks of cultivation and tested for the presence of either Mg++-dependent reverse transcriptase (RT) activity or HIV-1 p24 Gag antigen by ELISA.

For ex-vivo infection, CD4+ leukocytes from both CASE1 and her partner were isolated by negative selection from peripheral blood by Ficoll-Hypaque, washed
and suspended in complete medium and purified as described above. Cells were stimulated with PHA and 3 days later washed and infected with CCR5-dependent (R5) HIV-1<sub>Bal</sub> or CXCR4-dependent (X4) HIV-1<sub>LAI/IIIB</sub> at a multiplicity of infection of 0.2. Culture supernatants were collected every 3–4 days for up to 4 weeks and tested for the presence of RT activity.

**ELISpot assay for IFN-γ**

**Peptides**
The Variable Overlapping Peptide Scanning Design (VOPSD) technique [12] was used to design peptides derived from HIV-1 encoded antigens Tat (11 peptides, Repository number: ARP7102.1-30) and Gag (84 peptides, Repository number: ARP7114.1-84) kindly provided by the Centre for AIDS Reagents, National Institute for Biological Standards and Control (NIBSC HPA UK). Single peptides or peptide pools were used to stimulate PBMC collected in November 2009 and June 2011 at a final concentration of 2 μM. Validation of the VOPSD strategy was obtained by direct comparison with 15mer or 20mer peptide sets, as recently reported [12]. ELISpot for IFN-γ was performed as previously described [13], and detailed methods reported in the Additional file 1 section.

**Intracellular cytokine staining**
Thawed PBMC (>80% viable) were plated in a 96-well plate after 4 h of resting (EuroClone) at a concentration of 1x10<sup>6</sup> PBMC/well in complete RPMI medium [10% FBS (Lonza-BioWhittaker) in RPMI (Lonza-BioWhittaker)] with single/pools of HIV-1 derived peptides (2 μM) in the presence of a mixture of co-stimulatory anti-CD28 and anti-CD49d Ab (1.3 μg/ml each, Becton Dickinson). Cells were then treated and stained as previously described [13]. Detailed methods are reported in the Additional file 1 section.

**Results**

**Clinical history**
A previous female intravenous-drug user, (CASE1), was diagnosed with HIV-1 infection in 1993 (age: 23 years old) in the course of a pregnancy screening test; she was diagnosed with HIV-1 infection in 1993 (age: 23 years old). A previous female intravenous-drug user, (CASE1), was diagnosed with HIV-1 infection in 1993 (age: 23 years old). She also had a child born in 1994 by vaginal delivery who has remained uninfected.

In 1997 CASE1 was diagnosed with hepatitis C virus (HCV, genotype 3a) infection, becoming negative for HCV viremia with normal levels of transaminases in 2005 after therapy with Pegylated Interferon plus Rebetol (Additional file 1: Figure S1).

**Virological determinations and ex vivo infection of CASE1 CD4<sup>+</sup> T cells**
In June 2009 colon biopsies were taken for diagnostic purposes. Hematoxylin-eosin, Giemsa, PAS staining and transmission electron microscopy revealed normal histology of the intestinal mucosa, lack of inflammatory infiltrates, microbes, virions or cell injury (Additional file 1: Figure S2). The tissue was also negative for the presence of HIV-1 p24 Gag<sup>+</sup> cells by immunohistochemistry, although its viral DNA content was estimated to be 881 copies/10<sup>6</sup> cells. In vitro cultivation of either 6 colon biopsy histocultures or of colon-derived leukocytes (2x10<sup>6</sup> cells) co-cultivated with CD8-depleted T cell blasts of two seronegative donors were negative for virus replication in terms of either RT activity or p24 Gag production (data not shown). Furthermore, neither allogenic cultivation of 5x10<sup>5</sup> PBMC-purified CD4<sup>+</sup> cells from CASE1 with T cell blasts of two seronegative donors, nor direct cultivation of the same number of CASE1 cells in medium containing IL-2, induced virus replication (data not shown).

*Ex vivo* infection of CASE1 CD4<sup>+</sup> T cell blasts with HIV-1 R5<sub>Bal</sub> or X4<sub>LAI/IIIB</sub> strains resulted in virus replication, although at lower levels compared to those observed after infection of CD4<sup>+</sup> T cell blasts from her partner (Figure 1B and C).

**Sequence analysis of CASE 1 HIV-1 DNA**
Quantitative PCR from CASE1 plasma samples were repeatedly <50 copies HIV-1 RNA/ml (Figure 1A), and only 2 viral genomes were detected in a total of 9 mL of plasma from June and Nov 2009 by multiplex PCR to amplify both full length gag and gp120 env coding sequences (see Additional file 1). Her PBMC-associated HIV-1 DNA load in June, and Nov 2009 and in June 2011 was 28, <13 and 10 copies/10<sup>6</sup> cells, respectively. In the same dates, 23 gag- and 20 gp120 env- sequences (all with open reading frames) were obtained from a total of 21x10<sup>6</sup> PBMC.

All 15 PBMC-derived single genome HIV-1 gag coding sequences from June (N = 6) and Nov (N = 9) 2009 were
identical, as were 5 out of 8 sequences from June 2011 (Figure 2A). In the case of env (Figure 2B), all 4 PBMC sequences from June 2009 were identical; all 10 sequences from Nov 2009 encoded identical proteins (4 sequences had the same synonymous site mutation) and differed from the June 2009 population at only one amino acid. Three out of 6 env sequences from June 2011 were identical to the major Nov 2009 population and 2 out of 6 were identical to the minor Nov 2009 population. One env sequence and gag sequences from 3 June 2011 were subtle outliers, with an additional 5 or 6–17 changes, respectively, relative to the major virus populations (Figure 2). Despite this exceptional overall homogeneity in cell-associated viral DNA (Mean sequence diversity across all 3 time points =0.17% in gag and 0.08% in env), the single gag and env sequences obtained from the Nov 2009 plasma sample were significantly divergent from the PBMC-associated DNA sequences (Mean =1.1% in gag and 2.5% in env), although they each shared some of the mutations that distinguished the PBMC outlier sequences from Nov 2011. The changes in gag shared with each of the outlier PBMC led to the reversion of the B*57-associated AA substitution I147L in the immunodominant [14] B*57 epitope IW9, restoring the optimal CTL epitope sequence, and to the introduction of the T242N substitution in the TW10 epitope (Figure 2A), normally associated with CTL escape. No mutations were observed in the B*57-restricted epitopes KF11 or

**Figure 1** CASE1’s natural control of HIV-1 viremia. (A) Levels of peripheral CD4+ and CD8+ T cells, plasma viral RNA and the presence of anti-HIV-1 Ab in CASE1 plasma were monitored over 20 years of infection. Purified peripheral CD4+ T cells were isolated from CASE1 and infected with either an R5 (B) or an X4 (C) strain, resulting in detectable virus replication. Purified CD4+ T cells of her sexual partner supported higher levels of virus replication. Bars indicate error of the mean from duplicate cultures.
the B*14 epitope DA9 (Additional file 1: Figure S3A). Finally, 2 of the 3 shared non-synonymous site changes in env corresponded to acquisition of potential N-linked glycosylation sites (Figure 2B).

**CASE1 protective alleles**

Although not carrying the protective alleles CCR5-Δ32 and CCR2-64I, CASE1 does express HLA B and C alleles (B*14.02 and B*57.08; C*06 and C*08.02), previously associated, either alone [5,15] or in combination [16,17], with slow/non-progression in LTNP and low levels of viremia in the absence of cART assumption.

In addition, CASE1 possesses the C/C genotype in the rs9264942 (C/T) -35 SNP and the del/del polymorphism (rs67384697 G/deletion) mapping upstream to the 5′ and within the 3′ untranslated region of the HLA-C gene, respectively. These 2 SNPs have been reported to be in strong linkage disequilibrium being associated with control of HIV-1 viremia [5,6].

**Immunological phenotypes and immune responses**

CASE1 and her partner were found to have a distribution of B lymphocyte subpopulations comparable to those of uninfected individuals (Additional file 1: Table S1). Two
Figure 3 (See legend on next page.)
serum samples (tested as total and purified immunoglobulins) and cervico-vaginal derived Ab collected in June 2009 and Nov 2009 did not show neutralizing activity against a panel of different HIV clades and phenotypes (Additional file 1: Table S2). CASE1 and her partner also had a normal distribution of T cell subpopulations (Additional file 1: Table S3), and both expressed comparable levels of CXCR4 and CCR5 on CD4+ lymphocytes (Additional file 1: Figure S4).

The breadth and magnitude of T-cell responses were assessed using CASE1 PBMC collected in Nov 2009 and June 2011. T cell responses were observed against Gag and Nef but not against Tat peptides (Figure 3A). Recognition of Gag peptide pools was mainly directed against regions containing well-defined HLA-B*57-restricted Gag epitopes (pools D, E, G, H and I, Figure 3B), without appreciable differences between the two dates.

Among the peptides present in Gag pools D and E, those expressing HLA-B*57 restricted epitopes (I/LW9 peptides 25 and 26 from pool D; KF11 peptide 29 and 30 pool E) mounted the strongest T-cell response (Figure 3C) as reported for LTNP [18]. Interestingly, recognition of the B14-restricted epitope DA9, previously associated with virological control [19], was also observed (peptides 52 and 53 from pool H), whereas recognition of the B57 restricted epitope QW9 (peptide 54 and 55) was absent (Figure 3C). Moreover, recognition of pool I was not directed against the B57-restricted epitope TW10 (peptides 42 and 43), but toward the C06 restricted epitope KL9 (peptide 59, Figure 3C).

Among CD8+ T cells specific for HLA-B*57 (L/L)W9 restricted Gag epitopes (peptides 25 and 26), 34.6% expressed CCL4/MIP-1β and 50.5% were polyfunctional (Figure 3D). Recognition of Nef peptide pools was also mainly directed against regions containing well-defined HLA-B*57 and C06 restricted Nef epitopes (Figure 3E).

Conclusions
We here report that a woman (CASE1), who has been infected with HIV-1 for at least 20 years, has remained in good health with features of both EC and LTNP for the last 14 years. CASE1 co-expresses HLA-B (*14 and *57) alleles and HLA-B-mediated immune responses, together with HLA-C alleles (*06 and *08.02) associated with SNPs rs9264942C/C and rs67384697G/deletion and HLA-C restricted immune responses as her most evident features compatible with strong and durable control of HIV-1 infection and disease progression.

Although CASE1’s CD4+ T cells were infectable in vitro by both R5 and X4 HIV-1 strains, they showed lower levels of virus replication in comparison to those of the seronegative partner, suggesting the presence of restriction factors, such as p21 [20], limiting the virus replicative capacity in vitro and perhaps accounting for the lack of virus replication observed both in vivo and upon ex vivo cultivation of CASE1’s PBMC and gut-associated leukocytes.

Cell-associated HIV-1 DNA was detectable in PBMC and gut-mucosa derived cells at very low levels while gag sequences from single copy plasma RNA molecules and PBMC-associated HIV-1 DNA revealed the late emergence of mutations in two immunodominant HLA-B*57-restricted Gag epitopes co-existing on the same sequences. The mutation T242N observed in the TW10 epitope typically emerges early in infection and is known to effect CTL escape and impair viral fitness. However, this mutation is has not been associated with the EC status, being more frequently detected in B*57+ HIV-1 progressors [21].

The second mutation emerged in the I/LW9 B*57 associated epitope, restoring the original IW9 epitope with little or no impact on viral escape or fitness reported in prior studies. This behavior is reminiscent of EC who have extremely low levels of viral RNA in plasma, significant differences between contemporary viruses in the plasma and PBMC, and a high frequency of synonymous mutations in the plasma virus [22-25]. It is also noteworthy that HLA-B*57 epitope variation emerged in plasma-associated virus at the same sampling times of acquisition of two potential N-linked glycosylation sites in Env, including one that was previously implicated in the evasion of Ab neutralization [26]. These viral features, together with the persistence of CD8-mediated T cell responses, suggest the persistence of extremely low levels of virus replication in CASE1.
acquisition of several important amino acid substitutions in plasma-associated virus and in PBMC, in 2009 and 2011, respectively, suggests that her virological control may be waning.

In addition, CASE1 carries a unique combination of HLA-B protective alleles associated with CD8⁺ T cell-mediated control of HIV-1 replication and strong CD8⁺ T cells polyfunctional responses against HLA-B*57 and B*14-restricted Gag epitopes, as also observed in ELC and LTNP [27] that may account for the lack of CD4⁺ T cell depletion in peripheral blood and gut [28]. The higher levels of expression of HLA-C alleles carrying a deleted miR-148a/b binding site vs. those without a deleted site might facilitate greater T-cell recognition of infected cells [29]. In support of this interpretation CASE1 was also characterized by the presence of long lasting C*06-restricted T-cell responses against Nef epitopes.

HLA molecules play a central role in the control of HIV disease progression [17]. In this regard, CASE1 has multiple HLA features that were previously individually associated with control of HIV-1 viremia, including HLA class I alleles (HLA-B*057 and *014, HLA-C*06 and *0802) and two SNPs within the HLA-C locus (rs9264942C/C, and 263 del/del, 259 T/T, 261C/C, 266 T/T on rs67384697). Thus, co-expression of protective HLA-B and HLA-C alleles as well as of HLA-C SNPs, and the associated T cell immune responses, some of which polyfunctional [30], likely provide the strong and durable control of HIV-1 replication and disease progression in CASE1.

Additional file

Additional file 1: Table S1. Titer of anti-HIV neutralizing Ab in CASE1’s serum and mucosal-derived fluid. Table S2. Percentage of B lymphocyte phenotypes in CASE1, her partner, other Elite controllers and HIV-1 negative controls. Table S3. Peripheral T lymphocyte phenotype distribution (%) in CASE1 and her partner. Figure S1. CASE1’s HCV related clinical features. Figure S2. CASE1’s intestinal mucosa histological and ultrastructural analysis. Figure S3. Amino acid alignments of CASE1 Gag (A) and Env-gp120 (B) proteins. Figure S4. CXCR4 and CCR5 expression by CASE1’s and partner’s peripheral blood CD4⁺ T cells.

Competing interests
All authors declare that they have no competing interests.

Authors’ contributions
All authors contributed to conception and design of the study, acquisition and analysis of data. All authors contributed in drafting and revising the manuscript, and approved the final version.

Authors’ information
1James I Mullins, Mauro S Malnati and Massimo Alfano were co-last authors.

Acknowledgments
All authors would like to acknowledge the subject coded as CASE1 for her repeated willingness to provide biological samples. This work was supported by the EUROPRIS-Net of Excellence (grant number LSHP-CT-2006-037611 funded by EC under the Sixth Framework Programme), the NGIN consortium (grant number 201433 and the Combined Highly Active Anti-Retroviral Microbicides (CHAARM) grant 242135 funded by EC under the Seventh Framework Programme, the Italian Ministry of Health (grants 40H16 and 40H23), the Bill and Melinda Gates Foundation GHRC-CAVD Project, NIH grants to JIM (AI7734) and the Bioinformatics Core of the University of Washington Centers for AIDS Research (NIH AI27757). We thank the NIHSC-CFAR (UK) for providing viruses and monoclonal antibodies.

Author details
1Infectious Disease Unit, Busto Arsizio Public Hospital, P.le Solario n. 3, Busto Arsizio 21052, Varese, Italy. 2Viral Pathogens and Biosafety Unit, Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milan, Italy. 3Service Lab Fleming Research, Busto Arsizio, Varese, Italy. 4Human Virology Unit, Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milan, Italy. 5Viral Evolution and Transmission Unit, Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milan, Italy. 6Department of Translational Research, Istituto Giannina Gaslini, Genoa, Italy. 7Immunobiology of HIV Unit, Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Milan, Italy. 8Pathology Unit, Luigi Sacco Hospital, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. 9Departments of Microbiology, Medicine and Laboratory Medicine, University of Washington, Seattle, WA, USA. 10AIDS Immunopathogenesis Unit, Division of Immunology, Transplantation and Infectious Disease, San Raffaele Scientific Institute, Via Olgettina n. 58, Milan 20132, Italy. 11School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. 12Present address; Division of Experimental Oncology, Unit of Urology, URI; IRCCS Ospedale San Raffaele, Via Olgettina n. 60, Milan 20132, Italy.

Received: 16 August 2014 Accepted: 20 November 2014
Published online: 05 December 2014

References
1. Liu H, Hwangbo Y, Holte S, Lee J, Wang C, Kaupp N, Zhu H, Celum C, Corey L, McElrath MJ, Zhu T: Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 2004, 190:1055–1058.
2. Grabar S, Selingier-Leneman H, Abgrali S, Pialoux G, Weiss L, Costagliola D: Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV, AIDS 2009, 23(1):1163–1169.
3. Genovese L, Nebuloni M, Alfano M: Cell-mediated immunity in elite controllers naturally controlling HIV viral load. Front Immunol 2013, 4:286.
4. Almeida IR, Price DA, Papagno L, Arkoob ZA, Sause D, Bornstein E, Asher TE, Samit A, Schnuriger A, Theodorou J, Costagliola D, Rouzioux C, Agut H, Marcin C, Douek D, Autran B, Appay V: Superior control of HIV-1 replication by CD8⁺ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007, 204(24):2743–2748.
5. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, Zhang K, Gumbs C, Castagna A, Cossarizza A, Cozzi-Lepri A, De Luca A, Easterbrook P, Francioli P, Mallal S, Martinez-Picado J, Miro JM, Obel N, Smith J, Wymigger Y, Descombes P, Antonarakis SE, Letvin NL, MoMichael AJ, Haynes BF, Telsch A, Goldstein DB: A whole-genome association study of major determinants for host control of HIV-1. Science 2007, 317(5844):947–947.
6. Guer Simon J, Dalmasso C, Broot P, Meyer L, Westrop SJ, Imani N, Vicenzetti M, Morisca G, Tinelli M, Zanette Poma P, Bougard C, Potard V, Gotch FM, Casoli C, Marzorati A, Maciardi F, Defre P, Defransis GJ, Galli M, Autran B, Costagliola D, Poli G, Theodorou I, Riva A: Single-nucleotide polymorphism-defined class I and class III major histocompatibility complex genetic subregions contribute to natural long-term nonprogression in HIV infection. J Infect Dis 2013, 207(5):718–724. 7. Deeks SG, Autran B, Behnouh B, Benkranne M, Calinski S, Chomont N, Chun TW, Churchill M, Di Mascio M, Kallans C, Lefebvred L, Landay A, Lederman M, Levrou SR, Maldarelli F, Margolis D, Markowitz M, Martinez-Picado J, Mullins J, Mellors J, Moreno S, O'Doherty U, Palmer S, Pencicau MC, Peterlin M, Poli G, Routy JP, Rouzioux C, Silvestri G, Stevenson M, et al: Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012, 12(9):607–614.
8. Malnati MS, Scarletti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, Volpi R, Lusso P: A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc 2008, 3(1):1240–1248.
therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006, 80:6461–6467.

22. Bailey JR, Brennan TP, O’Connell KA, Siliciano RF, Blankson JN: Evidence of CD8+ T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HL-A B*57+ elite suppressors. J Virol 2009, 83:888–97.

23. Salgado M, Brennan TP, O’Connell KA, Bailey JR, Ray SC, Siliciano RF, Blankson JN: Evolution of the HIV-1 nef gene in HL-A B*85+ positive elite suppressors. Retrovirology 2010, 7:94.

24. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Kamarova NL, Nowak MA, Hahn BH, Kowong FD, Shaw GM: Antibody neutralization and escape by HIV-1. Nature 2003, 422:307–312.

25. Migueles SA, Conners M: Long-term nonprogressive disease among untreated HIV-infected individuals: clinical implications of understanding immune control of HIV. JAMA 2010, 304:194–201.

26. Ferne AL, Hunt PW, Critchfield JW, Young DH, Morris MM, Garcia JC, Pollard RB, Yee HF Jr, Martin JN, Deeks SG, Shacklelt BK: Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009, 113:3978–3989.

27. Kulikarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A, Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M: Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature 2011, 472:495–498.

28. Shan L, Deng K, Shroff NS, Durand CM, Rabi SA, Yang HC, Zhang H, Margolick JB, Blankson JN, Siliciano RF: Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012, 36:496–501.